{"title":"Evolocumab 和 Inclisiran 双管齐下,进一步降低心血管风险极高的家族性高胆固醇血症患者的低密度脂蛋白胆固醇(PCSK9)。","authors":"R. Gingell , P. Das , Y.P. Teoh","doi":"10.1016/j.athplu.2023.07.020","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"54 ","pages":"Pages S4-S5"},"PeriodicalIF":1.4000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667089523000330/pdfft?md5=4e4e785e597fcb3bf3758ef3634cd22e&pid=1-s2.0-S2667089523000330-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation\",\"authors\":\"R. Gingell , P. Das , Y.P. Teoh\",\"doi\":\"10.1016/j.athplu.2023.07.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":72324,\"journal\":{\"name\":\"Atherosclerosis plus\",\"volume\":\"54 \",\"pages\":\"Pages S4-S5\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667089523000330/pdfft?md5=4e4e785e597fcb3bf3758ef3634cd22e&pid=1-s2.0-S2667089523000330-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667089523000330\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667089523000330","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation